The co-occurrence of myocardial dysfunction and peripheral insensate neuropathy in a streptozotocin-induced rat model of diabetes

Cardiovascular Diabetology

Volumn 13, Issue 1, 2014, Pages

  Marangoni, Maria N ^a   Brady, Scott T ^a   Chowdhury, Shamim A ^a   Piano, Mariann R ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Diabetic cardiomyopathy; Diastolic dysfunction; Insensate neuropathy; Norepinephrine; Systolic dysfunction

Indexed keywords

CALCITONIN GENE RELATED PEPTIDE; GLUCOSE; NORADRENALIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTONOMIC DYSFUNCTION; BODY WEIGHT; BRADYCARDIA; COMORBIDITY; CONTROLLED STUDY; DIABETIC CARDIOMYOPATHY; DIARRHEA; DIASTOLIC DYSFUNCTION; ECHOCARDIOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; GLUCOSE BLOOD LEVEL; HEART DILATATION; HEART FUNCTION; HEART LEFT VENTRICLE MASS; HEART MUSCLE; HEART VENTRICLE REMODELING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOHISTOCHEMISTRY; MALE; MASS SPECTROMETRY; NONHUMAN; NORADRENALIN URINE LEVEL; PERIPHERAL NEUROPATHY; POLYDIPSIA; POLYNEUROPATHY; POLYURIA; RAT; SENSORY NEUROPATHY; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; STREPTOZOTOCIN-INDUCED DIABETIC NEUROPATHY; SYSTOLIC DYSFUNCTION; WEIGHT REDUCTION;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC CARDIOMYOPATHIES; DIABETIC NEUROPATHIES; DISEASE MODELS, ANIMAL; MALE; RATS; RATS, INBRED F344;

EID: 84892392836     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-13-11     Document Type: Article

References (50)

1. Astrup AS. Cardiovascular morbidity and mortality in diabetes mellitus: prediction and prognosis. Dan Med Bull 2011, 58(8):B4152.
2. Boudina S, Abel ED. Diabetic cardiomyopathy revisited. Circulation 2007, 115(25):3213-3223. 10.1161/CIRCULATIONAHA.106.679597, 17592090.
3. Chung JO, Cho DH, Chung DJ, Chung MY. Association between diabetic polyneuropathy and cardiovascular complications in type 2 diabetic patients. Diabetes Metab J 2011, 35(4):390-396. 10.4093/dmj.2011.35.4.390, 3178700, 21977459.
4. Mogensen UM, Jensen T, Kober L, Kelbaek H, Mathiesen AS, Dixen U, Rossing P, Hilsted J, Kofoed KF. Cardiovascular autonomic neuropathy and subclinical cardiovascular disease in normoalbuminuric type 1 diabetic patients. Diabetes 2012, 61(7):1822-1830. 10.2337/db11-1235, 3379682, 22498696.
5. Pop-Busui R, Cleary PA, Braffett BH, Martin CL, Herman WH, Low PA, Lima JA, Bluemke DA. Association between cardiovascular autonomic neuropathy and left ventricular dysfunction: DCCT/EDIC study (Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications). J Am Coll Cardiol 2013, 61(4):447-454. 10.1016/j.jacc.2012.10.028, 23265339.
6. Pop-Busui R, Evans GW, Gerstein HC, Fonseca V, Fleg JL, Hoogwerf BJ, Genuth S, Grimm RH, Corson MA, Prineas R. Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care 2010, 33(7):1578-1584. 10.2337/dc10-0125, 2890362, 20215456.
7. DCCT The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The diabetes control and complications trial research group. N Engl J Med 1993, 329(14):977-986. DCCT.
8. Kuehl M, Stevens MJ. Cardiovascular autonomic neuropathies as complications of diabetes mellitus. Nat Rev Endocrinol 2012, 8(7):405-416. 10.1038/nrendo.2012.21, 22371159.
9. Hargreaves K, Dubner R, Brown F, Flores C, Joris J. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 1988, 32(1):77-88. 10.1016/0304-3959(88)90026-7, 3340425.
10. Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL. Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 1994, 53(1):55-63. 10.1016/0165-0270(94)90144-9, 7990513.
11. Dixon WJ. Staircase bioassay: the up-and-down method. Neurosci Biobehav Rev 1991, 15(1):47-50. 10.1016/S0149-7634(05)80090-9, 2052197.
12. Gu L, Pandey V, Geenen DL, Chowdhury SA, Piano MR. Cigarette smoke-induced left ventricular remodelling is associated with activation of mitogen-activated protein kinases. Eur J Heart Fail 2008, 10(11):1057-1064. 10.1016/j.ejheart.2008.08.009, 2610403, 18815071.
13. Kim SD, Beck J, Bieniarz T, Schumacher A, Piano MR. A rodent model of alcoholic heart muscle disease and its evaluation by echocardiography. Alcohol Clin Exp Res 2001, 25(3):457-463. 10.1111/j.1530-0277.2001.tb02235.x, 11290859.
14. Reuben DB, Talvi SL, Rowe JW, Seeman TE. High urinary catecholamine excretion predicts mortality and functional decline in high-functioning, community-dwelling older persons: MacArthur studies of successful aging. J Gerontol A Biol Sci Med Sci 2000, 55(10):M618-M624. 10.1093/gerona/55.10.M618, 11034236.
15. Boomsma F, Alberts G, van Eijk L, Veld AJ MIT, Schalekamp MA. Optimal collection and storage conditions for catecholamine measurements in human plasma and urine. Clin Chem 1993, 39(12):2503-2508.
16. Neubecker TA, Coombs MA, Quijano M, O'Neill TP, Cruze CA, Dobson RL. Rapid and selective method for norepinephrine in rat urine using reversed-phase ion-pair high-performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Biomed Sci Appl 1998, 718(2):225-233. 10.1016/S0378-4347(98)00377-6, 9840432.
17. Obrosova IG. Diabetic painful and insensate neuropathy: pathogenesis and potential treatments. Neurotherapeutics 2009, 6(4):638-647. 10.1016/j.nurt.2009.07.004, 19789069.
18. Christianson JA, Ryals JM, Johnson MS, Dobrowsky RT, Wright DE. Neurotrophic modulation of myelinated cutaneous innervation and mechanical sensory loss in diabetic mice. Neuroscience 2007, 145(1):303-313. 10.1016/j.neuroscience.2006.11.064, 1853280, 17223273.
19. Johnson MS, Ryals JM, Wright DE. Early loss of peptidergic intraepidermal nerve fibers in an STZ-induced mouse model of insensate diabetic neuropathy. Pain 2008, 140(1):35-47. 10.1016/j.pain.2008.07.007, 2602970, 18762382.
20. Lennertz RC, Medler KA, Bain JL, Wright DE, Stucky CL. Impaired sensory nerve function and axon morphology in mice with diabetic neuropathy. J Neurophysiol 2011, 106(2):905-914. 10.1152/jn.01123.2010, 3154824, 21653724.
21. Sugimoto K, Rashid IB, Shoji M, Suda T, Yasujima M. Early changes in insulin receptor signaling and pain sensation in streptozotocin-induced diabetic neuropathy in rats. J Pain 2008, 9(3):237-245. 10.1016/j.jpain.2007.10.016, 18331706.
22. Obrosova IG, Xu W, Lyzogubov VV, Ilnytska O, Mashtalir N, Vareniuk I, Pavlov IA, Zhang J, Slusher B, Drel VR. PARP inhibition or gene deficiency counteracts intraepidermal nerve fiber loss and neuropathic pain in advanced diabetic neuropathy. Free Radic Biol Med 2008, 44(6):972-981. 10.1016/j.freeradbiomed.2007.09.013, 3057075, 17976390.
23. Calcutt NA, Freshwater JD, Mizisin AP. Prevention of sensory disorders in diabetic Sprague-Dawley rats by aldose reductase inhibition or treatment with ciliary neurotrophic factor. Diabetologia 2004, 47(4):718-724. 10.1007/s00125-004-1354-2, 15298349.
24. Yoon YW, Lee DH, Lee BH, Chung K, Chung JM. Different strains and substrains of rats show different levels of neuropathic pain behaviors. Exp Brain Res 1999, 129(2):167-171. 10.1007/s002210050886, 10591890.
25. Shir Y, Zeltser R, Vatine JJ, Carmi G, Belfer I, Zangen A, Overstreet D, Raber P, Seltzer Z. Correlation of intact sensibility and neuropathic pain-related behaviors in eight inbred and outbred rat strains and selection lines. Pain 2001, 90(1-2):75-82.
26. Fecho K, Valtschanoff JG. Acute inflammatory and neuropathic pain in Lewis and Fischer rats. J Neuroendocrinol 2006, 18(7):504-513. 10.1111/j.1365-2826.2006.01442.x, 16774499.
27. Gomez F, De Kloet ER, Armario A. Glucocorticoid negative feedback on the HPA axis in five inbred rat strains. Am J Physiol 1998, 274(2 Pt 2):R420-R427.
28. Wichi R, Malfitano C, Rosa K, De Souza SB, Salemi V, Mostarda C, De Angelis K, Irigoyen MC. Noninvasive and invasive evaluation of cardiac dysfunction in experimental diabetes in rodents. Cardiovasc Diabetol 2007, 6:14. 10.1186/1475-2840-6-14, 1866223, 17462095.
29. Mihm MJ, Seifert JL, Coyle CM, Bauer JA. Diabetes related cardiomyopathy time dependent echocardiographic evaluation in an experimental rat model. Life Sci 2001, 69(5):527-542. 10.1016/S0024-3205(01)01141-9, 11510948.
30. Radovits T, Korkmaz S, Loganathan S, Barnucz E, Bomicke T, Arif R, Karck M, Szabo G. Comparative investigation of the left ventricular pressure-volume relationship in rat models of type 1 and type 2 diabetes mellitus. Am J Physiol Heart Circ Physiol 2009, 297(1):H125-H133. 10.1152/ajpheart.00165.2009, 19429826.
31. Cosyns B, Droogmans S, Weytjens C, Lahoutte T, Van Camp G, Schoors D, Franken PR. Effect of streptozotocin-induced diabetes on left ventricular function in adult rats: an in vivo Pinhole Gated SPECT study. Cardiovasc Diabetol 2007, 6:30. 10.1186/1475-2840-6-30, 2099422, 17937784.
32. Joffe II, Travers KE, Perreault-Micale CL, Hampton T, Katz SE, Morgan JP, Douglas PS. Abnormal cardiac function in the streptozotocin-induced non-insulin-dependent diabetic rat: noninvasive assessment with doppler echocardiography and contribution of the nitric oxide pathway. J Am Coll Cardiol 1999, 34(7):2111-2119. 10.1016/S0735-1097(99)00436-2, 10588232.
33. Becher PM, Lindner D, Frohlich M, Savvatis K, Westermann D, Tschope C. Assessment of cardiac inflammation and remodeling during the development of streptozotocin-induced diabetic cardiomyopathy in vivo: a time course analysis. Int J Mol Med 2013, 32(1):158-164.
34. Hoit BD, Castro C, Bultron G, Knight S, Matlib MA. Noninvasive evaluation of cardiac dysfunction by echocardiography in streptozotocin-induced diabetic rats. J Card Fail 1999, 5(4):324-333. 10.1016/S1071-9164(99)91337-4, 10634674.
35. Weytjens C, Franken PR, D'Hooge J, Droogmans S, Cosyns B, Lahoutte T, Van Camp G. Doppler myocardial imaging in the diagnosis of early systolic left ventricular dysfunction in diabetic rats. Eur J Echocardiogr 2008, 9(3):326-333.
36. Akula A, Kota MK, Gopisetty SG, Chitrapu RV, Kalagara M, Kalagara S, Veeravalli KK, Gomedhikam JP. Biochemical, histological and echocardiographic changes during experimental cardiomyopathy in STZ-induced diabetic rats. Pharmacol Res 2003, 48(5):429-435. 10.1016/S1043-6618(03)00191-9, 12967586.
37. Stables CL, Glasser RL, Feldman EL. Diabetic cardiac autonomic neuropathy: Insights from animal models. Auton Neurosci 2013, 177(2):74-80. 10.1016/j.autneu.2013.03.001, 23562143.
38. Mathias CJ. Autonomic diseases: clinical features and laboratory evaluation. J Neurol Neurosurg Psychiatry 2003, 74(Suppl 3):iii31-iii41. 1765633, 12933912.
39. Fushimi H, Inoue T, Matsuyama Y, Kishino B, Kameyama M, Funakawa S, Tochino Y, Yamatodani A, Wada H, Minami T, et al. Impaired catecholamine secretion as a cause of diabetic autonomic neuropathy. Diabetes Res Clin Pract 1988, 4(4):303-307. 10.1016/S0168-8227(88)80033-0, 3286167.
40. Kaul CL, Grewal RS. Increased urinary excretion of catecholamines and their metabolites in streptozotocin diabetic rat. Pharmacology 1980, 21(3):223-228. 10.1159/000137436, 7413723.
41. Tidholm A, Haggstrom J, Hansson K. Vasopressin, cortisol, and catecholamine concentrations in dogs with dilated cardiomyopathy. Am J Vet Res 2005, 66(10):1709-1717. 10.2460/ajvr.2005.66.1709, 16273901.
42. Schmid H, Forman LA, Cao X, Sherman PS, Stevens MJ. Heterogeneous cardiac sympathetic denervation and decreased myocardial nerve growth factor in streptozotocin-induced diabetic rats: implications for cardiac sympathetic dysinnervation complicating diabetes. Diabetes 1999, 48(3):603-608. 10.2337/diabetes.48.3.603, 10078563.
43. Gallego M, Setien R, Izquierdo MJ, Casis O, Casis E. Diabetes-induced biochemical changes in central and peripheral catecholaminergic systems. Physiol Res 2003, 52(6):735-741.
44. Kuncova J, Sviglerova J, Tonar Z, Slavikova J. Heterogenous changes in neuropeptide Y, norepinephrine and epinephrine concentrations in the hearts of diabetic rats. Auton Neurosci 2005, 121(1-2):7-15.
45. Kusmic C, Morbelli S, Marini C, Matteucci M, Cappellini C, Pomposelli E, Marzullo P, L'Abbate A, Sambuceti G. Whole-body evaluation of MIBG tissue extraction in a mouse model of long-lasting type II diabetes and its relationship with norepinephrine transport protein concentration. J Nucl Med 2008, 49(10):1701-1706. 10.2967/jnumed.108.054361, 18794257.
46. Ieda M, Kanazawa H, Ieda Y, Kimura K, Matsumura K, Tomita Y, Yagi T, Onizuka T, Shimoji K, Ogawa S, et al. Nerve growth factor is critical for cardiac sensory innervation and rescues neuropathy in diabetic hearts. Circulation 2006, 114(22):2351-2363. 10.1161/CIRCULATIONAHA.106.627588, 17101855.
47. Chottova Dvorakova M, Kuncova J, Pfeil U, McGregor GP, Sviglerova J, Slavikova J, Kummer W. Cardiomyopathy in streptozotocin-induced diabetes involves intra-axonal accumulation of calcitonin gene-related peptide and altered expression of its receptor in rats. Neuroscience 2005, 134(1):51-58. 10.1016/j.neuroscience.2005.03.058, 15951122.
48. Batulevicius D, Frese T, Peschke E, Pauza DH, Batuleviciene V. Remodelling of the intracardiac ganglia in diabetic Goto-Kakizaki rats: an anatomical study. Cardiovasc Diabetol 2013, 12(1):85. 10.1186/1475-2840-12-85, 3688305, 23758627.
49. Thackeray JT, Beanlands RS, Dasilva JN. Altered sympathetic nervous system signaling in the diabetic heart: emerging targets for molecular imaging. Am J Nucl Med Mol Imaging 2012, 2(3):314-334. 3477737, 23133819.
50. Richardson RJ, Grkovic I, Anderson CR. Immunohistochemical analysis of intracardiac ganglia of the rat heart. Cell Tissue Res 2003, 314(3):337-350. 10.1007/s00441-003-0805-2, 14523644.